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diabetic patients with soft tissue infections or osteomyelitis, and one to improving tolerance of Bacillus Calmette-Guérin (BCG) instillations in patients with bladder cancer. Regarding CBP, prulifloxacin was non-inferior to its comparators, with a trend towards better microbiological outcomes at follow-up. Regarding traveller's diarrhoea, prulifloxacin resulted in better clinical and microbiological outcomes compared with placebo. Finally, prulifloxacin decreased the adverse events associated with BCG instillations in patients with bladder cancer, without affecting cancer recurrence rates.
In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea. M a n u s c r i p t trachomatis analysis], respectively. At the follow-up visit, clinical improvement (significant NIH-CPSI reduction) was observed in 90 (82.6%) of 109 patients in the prulifloxacin group and 81 (79.4%) of 102 patients in the doxycycline group (P = 0.08). However, prulifloxacin was found to be superior (P < 0.001) to doxycycline in terms of mucosal anti-C. trachomatis IgA and seminal plasma IL-8 reduction.
Furthermore, in a RCT evaluating the clinical efficacy of co-administration of prulifloxacin with several plant extracts (Serenoa repens, Urtica dioica, quercetin and curcumin) in the CBP setting, 143 patients were randomised to receive a 2-week regimen of either combination therapy (n = 106) or prulifloxacin alone (n = 37) [27].
Clinical efficacy was evaluated at two follow-up visits, 1 month and 6 months after initiation of treatment, using the NIH-CPSI and the International Prostatic Symptom Score (IPSS). One month after the initiation of treatment, 89.6% of patients treated with the combination regimen and 27.0% of those receiving antibiotic alone did not report any symptoms (P < 0.01). Significant differences were also found between groups in terms of NIH-CPSI and IPSS reduction. Similar results were found at the 6month follow-up visit.
Prophylaxis in patients undergoing transrectal prostate biopsy
A RCT assessed the effectiveness of two prulifloxacin dosing regimens in patients undergoing transrectal prostate biopsy [28] . A total of 432 males were assigned to either a single 600 mg oral dose 3 h before the procedure (n = 210) or a 5-day course of prulifloxacin 600 mg once daily with the first dose given 3 h before the procedure (n = 222). The primary outcome was clinical effectiveness, defined as the absence of fever or other signs and symptoms of infection. The most frequent events M a n u s c r i p t were local symptoms (haematuria, haemospermia, urine retention) without occurrence of fever and were equally distributed among groups (17% vs. 14%).
These symptoms resolved spontaneously within a few days. Rates of fever were similar between groups (0.95% vs. 0.90%).
Prophylaxis in women undergoing surgical abortion
An Italian RCT sought to evaluate the efficacy of different dosing regimens of prulifloxacin in the prevention of infection caused by surgical abortion [29] . In total, 466 women were randomised to three groups receiving prulifloxacin 600 mg once daily: Group A (n = 153) for 5 days after abortion; Group B (n = 155) for 3 days after abortion; and Group C (n = 158) 1 day before and 2 days after abortion. Abortions were performed in a range of gestational ages between 6 weeks and 11 weeks.
Pelvic inflammatory disease rates were 10.5% in Group A, 7.1% in Group B and 2.5% in Group C. The regimen of Group C was more effective than that of Group A (P < 0.05), but not that of Group B. In summary, prulifloxacin administration 1 day before and for few days after abortion surgery may be an effective way to prevent gynaecological infections.
Diabetic foot infections
A cohort study assessed the effectiveness and safety of prulifloxacin as outpatient therapy in the treatment of 60 patients with mild or moderate diabetic foot infection (30 cases of soft tissue infection and 30 cases of osteomyelitis) [33] . A mild or moderate infection was characterised by the presence of purulent material and signs of local inflammation with or without fever and leukocytosis. In soft tissue infections, M a n u s c r i p t prulifloxacin 600 mg once daily was administered for at least 15 days, whereas in the case of osteomyelitis the minimum duration of treatment was 40 days. Teicoplanin (200 mg intramuscular for at least 15 days) and metronidazole (7.5 mg/kg thrice daily for 10-15 days) were added, respectively, in the case of isolation of meticillin- 
Gastrointestinal infections
A double-blinded RCT presented at the 2008 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America Annual Meeting sought to evaluate the potential role of prulifloxacin in the treatment of traveller's diarrhoea [30] . In total, 282 travellers were randomised to receive either prulifloxacin 600 mg (n = 187) or placebo (n = 95) once daily for 3 days. A test of cure (TOC) visit was carried out 1-3 days after the end of treatment, whilst a microbiological stool examination took place at baseline and 3-6 days after the end of treatment. Primary outcome was the duration of diarrhoea, defined as the time to last unformed stool (TLUS), whilst secondary outcomes were microbiological eradication and safety. Prulifloxacin was superior to placebo in terms of TLUS in the intention-to-treat (ITT), modified intention-to-treat (mITT) and microbiologically evaluable (ME) populations. Among patients treated with prulifloxacin, the median M a n u s c r i p t TLUS was 24.2 h in both the ME and mITT groups. The median TLUS in the placebo group was not determined because 52% of the subjects did not achieve wellness by the TOC visit. Microbiological eradication of causative pathogens, including E. coli, Salmonella, Campylobacter and Shigella, was observed in 80.9% and 52.7% of the subjects in the prulifloxacin and placebo groups, respectively (P < 0.01). Finally, prulifloxacin and placebo showed similar safety profiles.
A similar RCT (2009 ICAAC meeting) allocated 268 adult travellers with gastroenteritis to either prulifloxacin (n = 133) or placebo (n = 135) once daily for 3 days [31] . Prulifloxacin was superior to placebo in the ITT, mITT and ME populations regarding the resolution of diarrhoea (P < 0.01). Among prulifloxacin recipients, median TLUS after initiation of treatment was 33 h in the ITT and mITT groups and 32 h in the ME group. In the placebo group, a median TLUS could not be estimated.
Isolated pathogens, including enterotoxigenic and enteroaggregative E. coli, Shigella, Salmonella, Plesiomonas and Campylobacter spp., were eradicated in 67.0% and 27.2% of patients given prulifloxacin and placebo, respectively (P < 0.01).
Prophylaxis against BCG-associated toxicity in the treatment of carcinoma of the bladder
An unblinded RCT demonstrated that prophylactic treatment with prulifloxacin improves tolerance to BCG instillations in patients with bladder cancer [32] . A total of 72 patients having undergone transurethral resection were randomised to a group treated with a 3-day course of prulifloxacin once daily after each weekly instillation (n = 37) or to a control group that received only BCG induction treatment (n = 35).
Adverse events were self-reported after each instillation and were classified by the M a n u s c r i p t investigators as mild, moderate or severe according to a classification grid. Results showed that prulifloxacin significantly decreased the proportion of subjects with moderate (P = 0.03), severe (P = 0.008) and overall (P = 0.012) adverse events after the fourth instillation. Adverse events related to BCG therapy made more patients stop or delay the course of instillations in the control group (34%) than in the prulifloxacin group (19%) (P = 0.04).
Discussion
This review shows that there may be a role for prulifloxacin in the treatment of infections beyond its current indications. Specifically, prulifloxacin is a promising therapeutic agent for the treatment of bacterial prostatitis and traveller's diarrhoea. In addition, prulifloxacin is associated with decreased toxicity due to BCG treatment for bladder cancer.
One of the most troublesome infections of the male genital tract is CBP [34] . Given that the prostate tissue is an anatomic department not easily penetrated, a favourable pharmacokinetic profile of an antibiotic is of great importance [35] .
Ulifloxacin shows excellent penetration into prostate tissue, where its concentrations always exceed those in plasma. Mean prostate tissue/plasma concentration ratios following antibiotic administration ranged from 3.8 to 9.5 [36] . In addition, ulifloxacin is not only highly active against commonly involved Gram-negative pathogens (E. coli, K. pneumoniae, P. mirabilis) but also displays some activity against Grampositive bacteria, including Enterococcus and Staphylococcus spp., which have recently been found to play an important role in CBP [37, 38] . Another advantage of this antibiotic in the CBP setting is its immunomodulating effect. In vitro studies Page 13 of 33 A c c e p t e d M a n u s c r i p t indicated that it can modulate the expression of pro-inflammatory cytokines, the role of which is well established in chronic prostatitis [39, 40] . Ulifloxacin was also found to accumulate both in bacterial cells and polymorphonuclear neutrophils, where it acts on the morphology of microorganisms making them more prone to phagocytosis and enhances the phagocytic capacity of macrophages [41] [42] [43] . These are highly desirable properties in the treatment of persisting and recurrent infections such as CBP, since they create a hostile milieu for commonly involved bacteria [44] . Notably, Giannarini et al. [25] showed that prulifloxacin was microbiologically and clinically equivalent to levofloxacin, a reference drug for CBP [45] . This study also found a trend towards lower recurrence rates with prulifloxacin after 6 months.
The satisfactory accumulation of ulifloxacin in the gastrointestinal tract along with its potent activity against Gram-negative rods support its therapeutic potential in traveller's diarrhoea [6] . A large in vitro study comparing the activities of different antibiotics against a worldwide collection of gastroenteritis-producing pathogens indicated that ulifloxacin was highly active against E. coli, Shigella, Salmonella, Yersinia, Aeromonas, Plesiomonas and Vibrio spp. [minimum inhibitory concentrations for 90% of the organisms (MIC 90 ) ≤0.06 g/mL] [7] . Its spectrum of activity was similar to that of ciprofloxacin, but ulifloxacin was two-to four-fold more potent. Only rare strains of E. coli (3%), Aeromonas (2%) and Campylobacter spp.
(14.7%) proved to be resistant [7] . These findings are in accordance with earlier data showing that the MICs of prulifloxacin against Enterobacteriaceae ranged from identical to four times lower compared with ciprofloxacin and from identical to eight times lower compared with levofloxacin and moxifloxacin [8, 9] .
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A c c e p t e d M a n u s c r i p t Prulifloxacin has also been tested in the field of gynaecological infections as it penetrates rapidly into female genital organs. Mean tissue/plasma ratios for gynaecological tissues ranged from 1.5 to 3 [46] . Another potential advantage is that ulifloxacin has very little impact on lactobacilli, the dominating vaginal microflora that inhibits the growth of pathogenic and opportunistic microorganisms predisposing to genital tract infections [47] . A study assessing the in vitro activity of ulifloxacin against 60 anaerobic clinical isolates from patients with gynaecological and obstetric infections showed that ulifloxacin was potent against Peptostreptococcus magnus [MIC for 50% of the organisms (MIC 50 ) = 0.2 g/mL] and P. bivia (MIC 50 = 0.78 g/mL) but not against B. fragilis (MIC 50 = 3.13 g/mL) [14] . Of note, the medication shows negligible activity against MRSA, which may cause serious gynaecological infections [48] .
In diabetic foot infections, S. aureus is the most commonly involved pathogen, whilst anaerobes such as B. fragilis also play an important role [49] . In this context, moxifloxacin might be a more rational treatment option than prulifloxacin since it is active against both of these pathogens [50] . Nevertheless, one should not ignore the potent activity of prulifloxacin against P. aeruginosa, which is often involved in diabetic foot infections [8, 10] .
An in vitro study indicated that prulifloxacin, along with ciprofloxacin, were the most active fluoroquinolones against ciprofloxacin-susceptible strains of P. aeruginosa (MIC 90 = 1 g/mL) [8] . Another study found that prulifloxacin was generally more potent than other fluoroquinolones against 300 multiple-resistant (resistant to more than three primary antipseudomonal drugs) P. aeruginosa isolates. Rates of M a n u s c r i p t susceptibility were also higher for ulifloxacin (72%) than for ciprofloxacin (65%) and levofloxacin (61%). In this study, a time-kill experiment found that prulifloxacin was superior to ciprofloxacin and levofloxacin with regard to the extent and speed of killing. Furthermore, the investigators assessed these fluoroquinolones in terms of mutant preventing concentration [51] [52] [53] , with prulifloxacin displaying the lowest values [10] . On the other hand, Montanari et al. [9] found that prulifloxacin and other fluoroquinolones were not active against community and nosocomial isolates of P.
aeruginosa.
A theoretical advantage of prulifloxacin in patients with cardiovascular disease, such as diabetic patients, might be its safety profile in terms of QT interval prolongation, which constitutes a common adverse event of fluoroquinolone therapy [54] . Recent data point to a potentially decreased risk of cardiotoxicity associated with prulifloxacin in comparison with other quinolones [55] [56] [57] [58] [59] . Specifically, in a clinical trial involving healthy patients the maximum QTc prolongation during a 5-day course was 4 ms for prulifloxacin and 12 ms for moxifloxacin [55] . The effect of prulifloxacin fell into the 0-5 ms range, which is considered to be a range with no risk for torsades de pointes [59] .
In conclusion, the addition of prulifloxacin to the therapeutic armamentarium has the potential to provide a useful alternative in the treatment of infections beyond the M a n u s c r i p t Studies included in the review (N = 9)
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